

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
 Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 Definitive Proxy Statement
 Definitive Additional Materials
 Soliciting Material under §240.14a-12

ZIOPHARM ONCOLOGY, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
- (1) Title of each class of securities to which transaction applies: _____
- (2) Aggregate number of securities to which transaction applies: _____
- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): _____
- (4) Proposed maximum aggregate value of transaction: _____
- (5) Total fee paid: _____
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
- (1) Amount Previously Paid: _____
- (2) Form, Schedule or Registration Statement No.: _____
- (3) Filing Party: _____
- (4) Date Filed: _____

On November 16, 2020, Ziopharm Oncology, Inc. posted the following material to www.ZiopharmForward.com.

Press Releases

November 16, 2020

[Ziopharm Oncology Appoints Mary Thistle to Board of Directors](#)

November 02, 2020

[Ziopharm Files Definitive Consent Revocation Statement and Sends Letter to Shareholders](#)

October 16, 2020

[Ziopharm Oncology Announces Receipt of Shareholders' Intent to Solicit Written Consents](#)

September 22, 2020

[Ziopharm Oncology Appoints Kevin Buchi to its Board of Directors](#)

July 22, 2020

[Ziopharm Oncology Names James Huang to Board of Directors](#)

Letters to Shareholders


November 02, 2020

[Letter to Shareholders](#)

SEC Filings

[Relevant Filings](#)

Sign Up For Email Updates



Delivering Significant Value to Shareholders

The Board of Directors and the Management Team at Ziopharm are committed to implementing the Company's strategy and to delivering significant value to its shareholders. We remain driven by our goal of developing technologies to help as many patients as possible. We have worked to put Ziopharm in what we believe to be a strong financial position to weather the ongoing COVID-19 pandemic and ensure visibility into key clinical data outputs in each of our programs.

November 16, 2020

[Ziopharm Oncology Appoints Mary Thistle to Board of Directors](#)

November 02, 2020

[Ziopharm Files Definitive Consent Revocation Statement and Sends Letter to Shareholders](#)

October 16, 2020

[Ziopharm Oncology Announces Receipt of Shareholders' Intent to Solicit Written Consents](#)

September 22, 2020

[Ziopharm Oncology Appoints Kevin Buchi to its Board of Directors](#)

July 22, 2020

[Ziopharm Oncology Names James Huang to Board of Directors](#)

Sign Up For Email Updates

Mary Thistle

DIRECTOR



Ms. Thistle has served as a member of Ziopharm's Board since November 2020. She is a Special Advisor and former Chief of Staff of the Bill & Melinda Gates Medical Research Institute. Ms. Thistle has more than 25 years of experience in finance, strategy and business development functions across different therapeutic areas, including gene therapy. Prior to joining the Bill & Melinda Gates Medical Research Institute, Ms. Thistle served as Chief Operating Officer of Dimension Therapeutics Inc. At Dimension, she oversaw the company's Series B financing and initial public offering, expanded the pipeline through strategic business development transactions, and led the sale of the company to Ultragenyx Pharmaceutical Inc. Prior, Ms. Thistle was the Senior Vice President, Business Development at Cubist Pharmaceuticals, where she was responsible for multiple acquisitions and assisted in the sale to Merck. Ms. Thistle held senior level positions at ViaCell Inc. in finance, operations and business development, and then served as Senior Vice President, Business Development at PerkinElmer after ViaCell was acquired. Ms. Thistle began her career in finance as a Certified Public Accountant. Ms. Thistle also serves on the Board of Directors of Homology Medicines and Enterome SA and is a graduate of the Women in Bio Boardroom Ready program.
